Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Novavax representatives will be making multiple oral presentations at the RSV Vaccines for the World conference, November 18-20, 2015 in La Jolla, California.

Poster, presentation titles and presenters are listed below:

  • “Biophysical Characterization of an RSV Nanoparticle Vaccine.”
    Oleg Borisov, Ph.D., Director, Analytical Development, Novavax, Inc.
  • “Randomized Phase 2 Trial of an RSV F Nanoparticle Vaccine in the Elderly: Epidemiology and Efficacy.”
    Vivek Shinde, M.D., Director, Clinical Development, Novavax, Inc.
  • “Phase 2 Trial of an RSV F Nanoparticle Vaccine in Pregnant Women Towards Maternal Immunization.”
    Allison August, M.D., Director, Clinical Research, Novavax, Inc.
  • “Sera Derived from Immunization with a Recombinant RSV F-protein Nanoparticle Vaccine Obtained from Cotton Rats and Women of Child-bearing Age Contains Antibodies Competitive with Neutralizing Monoclonals Against Multiple Epitopes.”
    Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc. (Original Source)

Shares of Novavax closed today at $7.01, up $0.29 or 4.32%. NVAX has a 1-year high of $15.01 and a 1-year low of $4.83. The stock’s 50-day moving average is $7.27 and its 200-day moving average is $9.64.

On the ratings front, Novavax has been the subject of a number of recent research reports. In a report issued on September 29, Piper Jaffray analyst Edward Tenthoff maintained a Buy rating on NVAX. Separately, on August 11, J.P. Morgan’s Cory Kasimov reiterated a Buy rating on the stock and has a price target of $14.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward Tenthoff and Cory Kasimov have a total average return of 8.3% and 0.0% respectively. Tenthoff has a success rate of 45.5% and is ranked #651 out of 3842 analysts, while Kasimov has a success rate of 42.8% and is ranked #2533.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.